AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials
Not a lab demo. Isomorphic Labs' AI-designed drugs are entering human trials—the first real-world validation that AI can discover medicines at scale.

Why it matters
DeepMind's drug-discovery spinoff is moving AI beyond benchmarks into clinical deployment. This is the earliest concrete proof point that AI-designed therapeutics can progress through regulatory gates, reshaping how pharma R&D allocates capital and talent.
The key facts
4 to knowIsomorphic Labs (DeepMind spinoff) advancing AI-designed drugs to human trials
Max Jaderberg (president) announced 'broad and exciting pipeline of new medicines' at WIRED Health 2026
First major pharma deployment of AI-designed compounds reaching clinical phase
Signals shift from AI capability claims to real-world therapeutic validation
Go to the source
Wired AIwired.com
Publisher excerpt: Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting pipeline of new medicines.”
